SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond

Lancet Diabetes Endocrinol. 2021 Jan;9(1):3-5. doi: 10.1016/S2213-8587(20)30374-0.

Author

Katherine R Tuttle¹

Affiliation

¹ Providence Medical Research Center, Providence Health Care, Spokane, WA 99204, USA; Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, WA, USA. Electronic address: katherine.tuttle@providence.org.

PMID: 33338414
DOI: 10.1016/S2213-8587(20)30374-0

No abstract available

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Cardiovascular Diseases*
Diabetes Mellitus*
Glucosides
Humans
Kidney
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2
dapagliflozin